Bone density in chronic schizophrenia with long-term antipsychotic treatment: preliminary study.
OBJECTIVE
Decreased bone mineral density has been found in the chronic schizophrenic patients who have been given a long-term administration of antipsychotics. Hyperprolactinemia from the antipsychotics and the negative symptom of schizophrenia were considered as the causes for this finding. In this study, the effect of hyperprolactinemia and the negative symptom of schizophrenia on bone mineral density was investigated on male schizophrenic patients.


METHODS
The cross-sectional study was carried out with the subjects of 45 male schizophrenic patients who have undertaken the monotherapy with risperidone, olanzapine and clozapine for at least one year. The demographic factors, clinical symtoms, bone mineral density and hematological test were examined for all the subjects.


RESULTS
No significant relationship was found between hyperprolactinemia and the decreased bone mineral density in the subjects. The negative schizophrenia symptom of the subjects showed a significant effect on the decreased bone mineral density.


CONCLUSIONS
The decreased bone mineral density finding in the male schizophrenic patients may be caused by the negative schizophrenia symptom rather than the hyperprolactinemia due to the antipsychotics. Additional studies are further required regarding other factors that may affect the decreased bone mineral density such as activity, calcium intake and exposure to sunlight.
National Naju Hospital, Naju, Korea.
Tae-Young
TY
Lee
Moon-Yong
MY
Chung
Hae-Kyung
HK
Chung
Jin-Hee
JH
Choi
Tae-Yong
TY
Kim
Hyung-Seok
HS
So
Rev Med Interne. 2004 Dec;25 Suppl 5:S552-9
15841947
Br J Psychiatry. 2007 Feb;190:129-34
17267929
Schizophr Res. 2003 Jan 1;59(1):17-8
12413637
Rheum Dis Clin North Am. 2000 Aug;26(3):569-91
10989513
J Bone Miner Res. 1993 Dec;8 Suppl 2:S475-80
8122515
Arch Gen Psychiatry. 1976 Mar;33(3):279-86
1259521
Exp Dermatol. 2004;13 Suppl 4:11-5
15507106
Bone. 2000 Jun;26(6):561-9
10831926
Psychosom Med. 1995 Sep-Oct;57(5):485-91
8552740
Int Clin Psychopharmacol. 2004 Jan;19(1):31-5
15101568
Clin Endocrinol (Oxf). 2000 Mar;52(3):319-27
10718830
Am J Psychiatry. 2003 Sep;160(9):1618-20
12944336
Am J Psychiatry. 2005 Jan;162(1):162-7
15625215
Am J Obstet Gynecol. 2006 Feb;194(2 Suppl):S3-11
16448873
Osteoporos Int. 1997;7(5):407-13
9425497
J Clin Psychiatry. 2000;61 Suppl 8:43-9; discussion 50-1
10811243
West J Med. 1991 Jan;154(1):63-77
2024511
Bull Hosp Jt Dis. 1999;58(4):197-201
10711369
Maturitas. 1996 Mar;23(2):193-207
8735357
J Clin Psychopharmacol. 2005 Jun;25(3):259-61
15876906
Br J Psychiatry. 2004 Jun;184:503-8
15172944
Clin Calcium. 2004 Apr;14(4):561-5
15577011
J Clin Invest. 2006 May;116(5):1186-94
16670759
Clin Biochem. 1997 Dec;30(8):573-93
9455610
Baillieres Clin Endocrinol Metab. 1995 Apr;9(2):359-66
7625989
Life Sci. 2002 Jul 19;71(9):979-92
12088758
J Clin Endocrinol Metab. 1998 Jul;83(7):2266-74
9661593
Schizophr Bull. 1996;22(3):447-54
8873295
Calcif Tissue Int. 1988 Oct;43(4):260-2
3145132
Biol Psychiatry. 1989 Dec;26(8):781-93
2590692
Br J Clin Pract. 1991 Autumn;45(3):189-6
1805916
J Endocrinol Invest. 2005 Jan;28(1):12-7
15816365
Psychiatr Pol. 2005 Nov-Dec;39(6):1157-71
16526182
Am J Psychiatry. 1981 Nov;138(11):1517
6117205
Endocr Pract. 1997 Jul-Aug;3(4):209-13
15251791
J Psychopharmacol. 2008 Mar;22(2 Suppl):70-5
18477623
J Gravit Physiol. 2002 Jul;9(1):P257-60
15002570
Nihon Rinsho. 2000 Jul;58 Suppl:163-5
11022707
Metabolism. 1998 Apr;47(4):425-8
9550540
Med Hypotheses. 2009 Apr;72(4):434-43
19155143
Psychoneuroendocrinology. 2003 Apr;28 Suppl 2:97-108
12650684
J Clin Psychiatry. 2008 Mar;69(3):385-91
18278991
Drugs Aging. 1998 Dec;13(6):421-34
9883398
CNS Drugs. 2007;21(8):641-57
17630817
Am J Med. 1997 Aug 18;103(2A):65S-71S; discussion 71S-73S
9302898
Drugs Aging. 2005;22(10):877-85
16245960